Inhibitors of HDAC have pleiotropic effects on cell cycle arrest, apoptosis, differentiation and inhibition of growth and angiogenesis [12,13], and have emerged as promising new therapeutic agents in multiple cancers, including those resistant to standard chemotherapy. The gene discussed is HDAC9; the disease is cancer.